HUTCHMED China Ltd (HCM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HUTCHMED China Ltd (HCM) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.12 Million ≈ $501.10 USD) by net assets (GBX1.25 Billion ≈ $152.24K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of HUTCHMED China Ltd for the company's overall valuation and market capitalisation.
HUTCHMED China Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how HUTCHMED China Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HUTCHMED China Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED China Ltd ranked by their cash flow conversion efficiency. Explore HCM cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Archtis Ltd
AU:AR9
|
-0.252x |
|
Sah Polymers Limited
NSE:SAH
|
0.014x |
|
Cliq Digital AG
XETRA:CLIQ
|
0.120x |
|
MiniLuxe Holding Corp
V:MNLX
|
0.103x |
|
DE&T Co. Ltd
KQ:079810
|
0.028x |
|
Han Express
KO:014130
|
-0.034x |
|
Carnavale Resources Limited
F:YBB
|
-0.009x |
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
-0.166x |
Annual Cash Flow Conversion Efficiency for HUTCHMED China Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2025. View HCM stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX1.25 Billion ≈ $152.03K |
GBX-64.67 Million ≈ $-7.87K |
-0.052x | -8137.94% |
| 2024-12-31 | GBX771.85 Million ≈ $93.91K |
GBX497.00K ≈ $60.47 |
0.001x | -99.78% |
| 2023-12-31 | GBX743.39 Million ≈ $90.45K |
GBX219.26 Million ≈ $26.68K |
0.295x | +169.93% |
| 2022-12-31 | GBX636.87 Million ≈ $77.49K |
GBX-268.60 Million ≈ $-32.68K |
-0.422x | -114.67% |
| 2021-12-31 | GBX1.04 Billion ≈ $126.48K |
GBX-204.22 Million ≈ $-24.85K |
-0.196x | -64.27% |
| 2020-12-31 | GBX518.95 Million ≈ $63.14K |
GBX-62.07 Million ≈ $-7.55K |
-0.120x | +53.75% |
| 2019-12-31 | GBX312.90 Million ≈ $38.07K |
GBX-80.91 Million ≈ $-9.84K |
-0.259x | -224.54% |
| 2018-12-31 | GBX412.25 Million ≈ $50.16K |
GBX-32.85 Million ≈ $-4.00K |
-0.080x | -332.07% |
| 2017-12-31 | GBX484.97 Million ≈ $59.01K |
GBX-8.94 Million ≈ $-1.09K |
-0.018x | +60.68% |
| 2016-12-31 | GBX204.06 Million ≈ $24.83K |
GBX-9.57 Million ≈ $-1.16K |
-0.047x | +48.90% |
| 2015-12-31 | GBX102.28 Million ≈ $12.44K |
GBX-9.38 Million ≈ $-1.14K |
-0.092x | -182.34% |
| 2014-12-31 | GBX119.88 Million ≈ $14.59K |
GBX13.36 Million ≈ $1.63K |
0.111x | +132.36% |
| 2013-12-31 | GBX104.84 Million ≈ $12.76K |
GBX5.03 Million ≈ $611.76 |
0.048x | -74.38% |
| 2012-12-31 | GBX83.65 Million ≈ $10.18K |
GBX15.66 Million ≈ $1.91K |
0.187x | +178.34% |
| 2011-12-31 | GBX77.33 Million ≈ $9.41K |
GBX5.20 Million ≈ $632.88 |
0.067x | +123.36% |
| 2010-12-31 | GBX68.81 Million ≈ $8.37K |
GBX-19.82 Million ≈ $-2.41K |
-0.288x | -286.53% |
| 2009-12-31 | GBX75.30 Million ≈ $9.16K |
GBX11.63 Million ≈ $1.41K |
0.154x | +191.37% |
| 2008-12-31 | GBX84.43 Million ≈ $10.27K |
GBX-14.27 Million ≈ $-1.74K |
-0.169x | -91.86% |
| 2007-12-31 | GBX97.61 Million ≈ $11.88K |
GBX-8.60 Million ≈ $-1.05K |
-0.088x | -166.27% |
| 2006-12-31 | GBX109.98 Million ≈ $13.38K |
GBX-3.64 Million ≈ $-442.64 |
-0.033x | -106.81% |
| 2005-12-31 | GBX-28.01 Million ≈ $-3.41K |
GBX-13.60 Million ≈ $-1.65K |
0.485x | -- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more